News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

News

Biotech Scribe strikes gene editing deal with Lilly subsidiary

May 16, 2023

Biopharma Dive

Read Now

Press Release

Biotech Scribe strikes gene editing deal with Lilly subsidiary

May 16, 2023

Biopharma Dive

Read Now

News

Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration

May 16, 2023

Genetic Engineering & Biotechnology News

Read Now

Press Release

Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration

May 16, 2023

Genetic Engineering & Biotechnology News

Read Now

News

Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit

May 16, 2023

Fierce Biotech

Read Now

Press Release

Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit

May 16, 2023

Fierce Biotech

Read Now

News

Scribe pens $1.5B-plus CRISPR tech deal with Lilly

May 16, 2023

BioWorld

Read Now

Press Release

Scribe pens $1.5B-plus CRISPR tech deal with Lilly

May 16, 2023

BioWorld

Read Now

News

Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal

May 16, 2023

Seeking Alpha

Read Now

Press Release

Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal

May 16, 2023

Seeking Alpha

Read Now

News

Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal

May 16, 2023

San Francisco Business Times

Read Now

Press Release

Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal

May 16, 2023

San Francisco Business Times

Read Now

News

Influential Women 2023: Svetlana Lucas, Chief Business Officer, Scribe Therapeutics

October 6, 2023

San Francisco Business Times

Read Now

News

This Scientist Is Building Custom Gene-Editing Tools

July 25, 2023

Forbes

Read Now

News

Scribe Therapeutics' Gene-Editing Tech Attracts Pharma Partners

July 20, 2023

Wall Street Journal

Read Now

News

Scribe Therapeutics and Sanofi collaborate on in vivo therapies for sickle cell disease

July 18, 2023

BioWorld

Read Now

News

Sanofi expands collaboration with Scribe on CRISPR genome editing

July 18, 2023

Seeking Alpha

Read Now

News

East Bay's Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease

July 18, 2023

San Francisco Business Times

Read Now

Press release

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Read Now

Press release

Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024

October 30, 2024

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Conferences

September 12, 2024

Read Now

Press release

Scribe Therapeutics Presents Data Demonstrating Highly Potent Gene Editing In Vivo, Including Saturated Editing of Hepatocytes in NHPs, by an Engineered XE Genome Editor; Showcases Novel Epigenetic Editing Capabilities at 2024 ASGCT Annual Meeting

May 10, 2024

Read Now

Press release

Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

April 22, 2024

Read Now

Press release

Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

March 6, 2024

Read Now

Publications

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publications

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publications

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publications

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publications

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publications

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publications

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publications

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now